RSV-prevention in children guided by a web-based early warning system

Area of Science:

• Pediatric infectious diseases
• Epidemiology
• Public health surveillance

Background:

• Passive immunization with palivizumab for respiratory syncytial virus (RSV) is costly and logistically demanding, with a standard recommendation of five monthly injections.
• The onset and duration of the RSV season exhibit significant variability, often displaying a dual rhythm in temperate climates.
• A rigid vaccination schedule may not align with actual RSV epidemiological patterns, potentially leading to suboptimal protection.

Purpose of the Study:

• To evaluate the effectiveness of a web-based early warning system for pathogen-specific surveillance.
• To determine if epidemic-synchronous administration of palivizumab can improve upon a fixed monthly injection schedule.
• To assess the potential for increased efficiency and cost savings in RSV prevention strategies.

Main Methods:

• Implementation of a web-based early warning system (PID-ARI.net) for real-time surveillance of respiratory pathogens.
• Weekly online publication of surveillance data to guide clinical interventions.
• Prospective enrollment of children with lower airway infections, utilizing 19-valent multiplex RT-PCR on nasopharyngeal aspirates from multiple German regions.

Main Results:

• Over a four-year period (July 1999-June 2003), a rigid five-month palivizumab application schedule would have been misaligned with RSV activity in 25% of months.
• The recommended vaccination campaign start was too early in two seasons and too late in one, with two seasons ending prematurely, leaving infants at risk.
• The surveillance data indicated significant deviations from the standard prophylactic schedule, highlighting the need for dynamic intervention timing.

Conclusions:

• The PID-ARI.net system represents a novel, pathogen-specific, comprehensive, and rapid surveillance network for respiratory pathogens in Europe.
• This system enables epidemic-synchronous application of passive immunization, such as with palivizumab, enhancing its efficacy.
• Optimizing the timing of palivizumab administration through real-time surveillance has the potential to increase effectiveness and reduce healthcare costs.